EN DE

Wooree Bio Co.Ltd (082850) Fair Value & Analysis

Technology · KR · Market cap 52.4B KRW

WB Wooree Bio Co.Ltd 082850 · KQ
Price from Aug 13, 2026897.00 KRW
Fair Value1,610 KRW
Upside+79.5%
Quality41/100
Watch Wooree Bio Co.Ltd for free, get notified when fair value or trend changes. Watch for free
Weak Growth
Thin margins · 2.1% net margin
Low debt · generates free cash flow
1.10% dividend yield
Trails peers (3/10)
Narrow moat 41/100
Evidence: Medium Range 1,610 KRW – 1,619 KRW Share as image

Fair value as of: Aug 13, 2026

From 15 valuation models · updated 6 days ago

Fair value updated Aug 13, 2026, revised from 1,617 KRW to 1,610 KRW (−0.4%) since Jul 20, 2026. Share price −16.4% over the past month.

Below-average quality, screening 79% undervalued on our models.

Fair value for all 35,000+ stocks, review alerts and the diversification check: 14 days of Pro free, no card.

What matters now

  • The large discount to fair value meets weak quality (41/100). That raises the risk this is a value trap rather than a bargain.
  • The price is below even our cautious bear case (1,610 KRW). The market is more pessimistic than our downside scenario.
  • The models converge in a tight band (1,610 KRW to 1,619 KRW), unusually little disagreement for a valuation.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (5 years)

6,163 KRW 859.00 KRW Fair Value 1,610 KRW Mar 2021 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.

How to read this chart

60‑month range 859.00 KRW – 6,163 KRW · fair‑value band 1,610 KRW – 1,619 KRW · the 897.00 KRW price screens below the 1,610 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 13, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Wooree Bio Co.Ltd (082850) currently trades at 897.00 KRW, while our model-based Fair Value estimate is 1,610 KRW, implying the stock looks roughly 79.5% undervalued today. The Quality Score stands at 41/100 (below-average quality), in the Technology sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium), always confirm before acting.

Over the trailing twelve months, Wooree Bio Co.Ltd generated revenue of 1.5T KRW at a net margin of 2.1%. Revenue declined 11.6% year over year. It earns a return on equity of 97.3%. Net debt stands at 9.6B KRW. Fundamentals as of Aug 13, 2026

Our scenario range runs from 1,610 KRW (bear case) to 1,619 KRW (bull case); at 897.00 KRW, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 66% below its 52-week high, currently below its 200-day average. For context, the median of 10 Technology peers we cover trades at -56% fair-value upside, at 79%, 082850 screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model Bear Bear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull Bull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
Growth DCF 4,463 KRW 5,538 KRW 7,376 KRW 80
Rev-Margin DCF 2,714 KRW 2,939 KRW 3,256 KRW 74
ROIC Compounder 1,619 KRW 1,637 KRW 1,653 KRW 72
All 15 models by family
DCF Models
FCF DCF 4,332 KRW 5,439 KRW 7,490 KRW 38
5Y Revenue Exit 2,714 KRW 2,872 KRW 3,096 KRW 39
5Y EBITDA Exit 7,353 KRW 10,906 KRW 15,610 KRW 41
10Y Revenue Exit 3,322 KRW 3,498 KRW 3,648 KRW 36
10Y EBITDA Exit 6,144 KRW 8,465 KRW 10,995 KRW 37
Earnings-Based
EPV 1,619 KRW 1,637 KRW 1,653 KRW 59
Dividend Discount
Gordon GGM 209.36 KRW 229.15 KRW 259.32 KRW 70
DDM Multi-Stage 209.36 KRW 262.67 KRW 337.40 KRW 61
Multiples
EV/EBIT 1,916 KRW 2,050 KRW 2,185 KRW 53
EV/EBITDA 10,551 KRW 13,564 KRW 16,577 KRW 54
EV/Revenue 1,716 KRW 1,804 KRW 1,891 KRW 43
Asset-Based
NCAV (Graham) 2,394 KRW 3,208 KRW 4,788 KRW 50
Growth DCF
Growth DCF 4,463 KRW 5,538 KRW 7,376 KRW 80
Rev-Margin DCF 2,714 KRW 2,939 KRW 3,256 KRW 74
Economic Profit
ROIC Compounder 1,619 KRW 1,637 KRW 1,653 KRW 72

Widest divergence: DCF Models (5,439 KRW) versus Dividend Discount (229.15 KRW). Highest evidence: Growth DCF (80).

Notify me when 082850 reaches fair value

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.

Key figures & financial health

Revenue (TTM) 1.5T KRW
Revenue growth (YoY) -11.6%
Net margin 2.1%
Return on equity 97.3%
Free cash flow 12.4B KRW FY2025
Operating margin 2.7%
More key figures
Dividend yield 1.1%
EPS growth (YoY) -5.7%
Net debt 9.6B KRW FY2025

Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 41/100

Of which business quality 38 · Market factors (momentum, volatility) 4

Profitability 30
Margins and returns on capital today
Quality Growth 19
Are margins and returns improving?
Cashflow 15
Earnings quality: real cash, not paper profit
Fin. Strength 37
Balance sheet, leverage, solvency risk
Investment 74
Disciplined investing over empire-building
Low Volatility 12
Calm price path (market factor)
Momentum 0
Price trend over the last 3–12 months (market factor)
52W Momentum 0
Distance to the 52-week high (market factor)
Net Issuance 80
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

Wooree Bio Co.,Ltd, together with its subsidiaries, engages in the production and sale of flexible circuit boards in South Korea.

Full company description

Wooree Bio Co.,Ltd, together with its subsidiaries, engages in the production and sale of flexible circuit boards in South Korea. The company also offers LED packages and modules; surface mounting technology products; separators for secondary batteries; backlight parts for thin film transistor-liquid crystal displays; sells and assembles TVs; and TV and LCD monitor components. In addition, it provides health supplementary food; and provides natural materials for cosmetics, food, and functional supplement applications, as well as provides vertical farm services. The company was formerly known as Wooree ETI Co., Ltd. and changed its name to Wooree Bio Co.,Ltd in March 2019. Wooree Bio Co.,Ltd was founded in 2000 and is headquartered in Ansan, South Korea.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Wooree Bio Co.Ltd reported revenue of 1.0T KRW in FY2025 versus 1.5T KRW in FY2021, a compound −9.3%/yr. Reported net income was −9.4B KRW in FY2025.

Growth Quality 37/100
Revenue growth is weak, negative or inconsistent.
Latest Revenue (FY 2025)
1.0T KRW
Latest YoY
−15.6%
Avg. growth/yr (3Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
−8.3%
Avg. growth/yr (5Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
−8.5%
Avg. growth/yr (17Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+4.2%
Revenue −9.3%/yr
FY21 1.5T KRW
FY22 1.4T KRW
FY23 1.3T KRW
FY24 1.2T KRW
FY25 1.0T KRW
Net income
FY21 33.2B KRW
FY22 21.8B KRW
FY23 15.6B KRW
FY24 4.7B KRW
FY25 −9.4B KRW

Watch 082850: get an alert when its fair value changes →

Share or link this analysis
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "Wooree Bio Co.Ltd Fair Value". https://www.fairvalue-calculator.com/stock/082850

Peer Group

Semiconductors & Semiconductor Equipment · 48 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 41 · Bottom 25%
Fair Value upside +80% · Top 25%
Return on equity (TTM) 97% · Below median
Return on assets 4% · Below median
Net margin (TTM) 2% · Below median
Operating margin (TTM) 3% · Below median
Revenue growth -12% · Bottom 25%
Dividend yield (TTM) 1.1% · Above median
Debt / equity 0.21× · Higher than 75% of peers

Valuation Multiples vs Semiconductors & Semiconductor Equipment median · lower = cheaper

P/FCF 0.0× · Cheaper than 75% of peers

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE100 · sector 0
FUTURE0 · sector 97
PAST100 · sector 100
HEALTH90 · sector 99
DIVIDEND22 · sector 17

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Semiconductors & Semiconductor Equipment stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).

Stock Price Fair Value vs Fair Value
TES Co 095610 144,000 KRW 57,543 KRW -60%
Eugene Technology Co 084370 129,200 KRW 47,495 KRW -63%
TSE Co 131290 256,000 KRW 83,925 KRW -67%
ISC Co 095340 159,800 KRW 61,198 KRW -62%
PSK HOLDINGS Inc 031980 112,200 KRW 74,962 KRW -33%
Jeju Semiconductor Corp 080220 87,000 KRW 23,830 KRW -73%
Tokai Carbon Korea Co 064760 229,000 KRW 154,525 KRW -33%
HANA Micron Inc 067310 36,650 KRW 16,102 KRW -56%
RFHIC Corporation 218410 51,000 KRW 29,096 KRW -43%
S&S Tech Corporation 101490 44,850 KRW 60,781 KRW +36%

Compare Wooree Bio Co.Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Technology stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is Wooree Bio Co.Ltd (082850) overvalued or undervalued?
As of Aug 13, 2026, our model estimates a fair value of 1,610 KRW versus the last price from Aug 13, 2026 of 897.00 KRW, about +79% (undervalued).
What is the fair value of 082850?
Our model-based fair value for Wooree Bio Co.Ltd is 1,610 KRW (as of Aug 13, 2026), built from audited fundamentals. Last price (from Aug 13, 2026): 897.00 KRW.
What is the quality score of 082850?
Wooree Bio Co.Ltd has a Quality Score of 41/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of Wooree Bio Co.Ltd (082850)?
Wooree Bio Co.Ltd reported trailing-twelve-month revenue of about 1.5T KRW (latest available figure, as of Aug 13, 2026).
What is the net profit margin of 082850?
The net profit margin of Wooree Bio Co.Ltd is about 2.1%, meaning it keeps roughly 2.1% of revenue as net income. Based on the latest reported figures.
Does Wooree Bio Co.Ltd pay a dividend?
Wooree Bio Co.Ltd currently shows a dividend yield of about 1.10% relative to its recent price (as of Aug 13, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track Wooree Bio Co.Ltd and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.